DBVT

DBV Technologies S.A.

0.81 USD
-0.02 (-3.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

DBV Technologies S.A. stock is down -10.56% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 March’s closed higher than February. 100% of analysts rate it a buy.

About DBV Technologies S.A.

DBV Technologies S.A. engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus.